INTRODUCTION
Residual viraemia is detectable in the majority of highly active antiretroviral therapy (HAART)-treated human immunodeficiency virus (HIV)-infected subjects with plasma viral load ,50 copies ml 21 (Finzi et al., 1999; Dornadula et al., 1999; Havlir et al., 2003) and persists for at least 7 years of successful HAART (Palmer et al., 2008) . Long-lived cells infected before HAART initiation have been proposed as a major source of this low-level viraemia (Maldarelli et al., 2007) , the implications of which have not been fully explored. Studies suggest that residual viraemia does not increase after successful HAART simplification to a regimen based on lopinavir/ritonavir alone (McKinnon et al., 2006) , and that in the mid term its magnitude is not associated with virological failure in subjects on continuous HAART (Havlir et al., 2005) . No data have been reported on the impact that Structured Treatment Interruptions (STIs), a controversial strategy proposed to simplify therapy and reduce drug exposure (Ananworanich & Hirschel, 2007) , may have on residual viraemia once HAART is reinstituted and patients regain a full virological response. In the present study, low-level HIV-1 RNA was quantified in subjects undergoing 24 months of intermittent HAART, and the results were compared with those found in patients continuing HAART.
METHODS
The present study is an exploratory, unplanned analysis involving 58 subjects enrolled in the ISS-PART, a randomized, controlled trial comparing 24 months of continuous (arm A) versus intermittent (arm B) HAART in 273 subjects with chronic HIV infection and persistent suppression of viral replication (Palmisano et al., 2007) . Intermittent HAART consisted of five STIs of 1, 1, 2, 2 and 3 months duration, each followed by 3 months of therapy. Any regimens in the Treatment Guidelines in force at the time (year 2001) could be used, including those based on an unboosted protease inhibitor.
Residual HIV-1 plasma viraemia was measured using an assay based on a modified Roche Amplicor HIV-1 Monitor test, version 1.5, as previously described (Palmisano et al., 2005) . The limit of detection was 2.5 copies of HIV-1 RNA ml 21 . Plasma samples collected at time 0 and after 24 months were analysed. The latter time point corresponded to the end of the final 3-month therapy period in arm B. The Wilcoxon test for dependent samples was used to compare HIV-1 RNA values at baseline and after 24 months within the groups. The Mann-Whitney test was used to compare HIV-1 RNA levels and change over time in the two arms. Proportions of patients with detectable (.2.5 copies ml 21 ) HIV-1 RNA at baseline and 24 months in the two arms were compared by the x 2 test. In arm B, Pearson's correlation coefficient was used to assess the relationship between HIV RNA values measured during the last HAART interruption and at month 24.
RESULTS AND DISCUSSION
Thirty-three arm A and 25 arm B subjects were included in this study. Table 1 summarizes their main clinical and demographic characteristics, which were not statistically different from those of the original ISS-PART population.
No statistically significant differences were found between arm A and B for all the considered variables. All patients completed the 24 month follow-up according to the protocol and all of them had less than 50 copies ml 21 of plasma HIV-1 RNA at the end of it by the standard Roche Amplicor HIV-1 Monitor test. The total time spent off therapy for subjects in arm B was 274 days (median, range 237-298).
At baseline, median (range) plasma HIV-1 RNA values were 2.5 (2.5-137) copies ml 21 in arm A and 2.5 (2.5-82.5) copies ml 21 in arm B (P50.34). After 24 months, HIV-1 RNA median values were 2.5 (2.5-97.7) copies ml 21 in arm A (P50.74 with respect to baseline) and 8.3 (2.5-49.3) copies ml 21 in arm B (P50.08 with respect to baseline) (Fig. 1) . Comparing the median change in HIV-1 RNA values in the two arms yielded a significant difference: 0 (range 2125 to +82.7) copies ml 21 in arm A and 2.1 (range 280 to +46.8) copies ml 21 in arm B (P50.024). Detectable (.2.5 copies ml
21
) levels of HIV-1 RNA were found in 16/33 (48.5 %) subjects in arm A and 10/25 (40 %) in arm B (P50.52) at baseline and in 15/33 (45 %) in arm A and 17/25 (68 %) in arm B after 24 months, with a trend to an increase in arm B only (P50.06) (Fig. 1) In group B, no correlation was found between the magnitude of HIV-1 RNA rebound during the last STI and the values of residual viraemia at month 24.
This study was conducted to assess whether repeated HAART interruptions may influence the levels of residual HIV-1 viraemia in subjects who regain virological suppression after restarting HAART. For this purpose, an ultrasensitive assay with a limit of detection of 2.5 copies of HIV-1 RNA ml 21 was used to measure residual viraemia before and after 24 months of continuous or intermittent HAART in the context of the ISS-PART clinical trial. In agreement with literature data (Havlir et al., 2003) , at baseline less than 50 % of patients in the whole study population had detectable (.2.5 copies HIV-1 RNA ml 21 ) residual viraemia, with a median value of 2.5 copies ml 21 . After 2 years, these values remained unchanged in subjects on continuous HAART; this finding is consistent with the hypothesis that a stable set point of low-level HIV-1 RNA is usually achieved after a few months of HAART (Maldarelli et al., 2007) and persists for several years thereafter (Palmer et al., 2008) . Conversely, in subjects undergoing five cycles of 'on/off' therapy, the number of HIV-1 RNA copies ml 21 tended to increase, as did the proportion of individuals with detectable viraemia. A significant difference was found when the variations in residual viraemia occurring in the two arms after 24 months were compared. These small changes would have gone unnoticed using conventional assays for HIV-1 RNA quantification; in fact, all patients in the two arms had plasma viraemia values ,50 copies ml 21 after 24 months by using the standard Amplicor assay. The mechanisms for this apparent increase in residual viraemia in subjects receiving intermittent HAART in the ISS-PART study are not clear. One explanation could be that 3 months of HAART were insufficient to regain preinterruption viraemia values; however, the absence of correlation between the magnitude of viral rebound during the last interruption and the values of HIV-1 RNA measured at month 24 makes this hypothesis unlikely, although it cannot be ruled out. On the other hand, a gradual reseeding of viral reservoirs during five successive STIs seems to be a plausible explanation (Frost et al., 2002) .
This study has some limitations. The first of these is the relatively small number of patients, which does not allow the capture of possible differences related to the type of regimen. Secondly, two time points only could be analysed for each patient, baseline and month 24, allowing the description of the overall effect of intermittent therapy on residual viraemia but not its dynamics. The strength of the reported observations is represented by the availability of a control group, the high level of patient compliance to study protocol and the homogeneity of the tested population to that of the original ISS-PART study.
In conclusion, the results obtained using a more sensitive method for HIV-1 RNA quantification suggest that 24 months of continuous or intermittent HAART have a different impact on residual viraemia. Further studies with longer follow-up are recommended to confirm these findings and to assess whether they can influence the long-term risk of virological failure and viral evolution. Residual HIV viraemia and HAART interruptions
